UK Biobank (core renewal)

Lead Research Organisation: UK Biobank

Abstract

UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometry, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. From 2017 onwards, the identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period.

Technical Summary

The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. By 2022, there will start to be sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants (although research related to conditions present at baseline has already started).

Hence, the chief emphasis for the past 5 years has been on preparing UK Biobank for effective use as a prospective resource by the widest possible range of researchers. This activity has included: developing resource access management systems; conducting repeat assessments in 20,000 participants; establishing record linkage for death, cancer and hospitalisation; piloting large-scale characterisation of commoner conditions; enhancing participant phenotyping; preparing for imaging assessments; and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.

During the next few years, it is intended to: extend cohort-wide record linkage to primary care health records and conduct direct participant follow-up (e.g. for cognitive function); further develop and implement large-scale identification and characterisation of many different types of health outcome; streamline the research access systems, and improve methods for processing, presenting and providing linked healthcare data to researchers; conduct imaging assessments in 100,000 participants; develop and implement further enhancements (such as cardiac monitoring and further sample collection and assays); and make increasing amounts of genotype and biomarker data available. Efforts will also be made to ensure that researchers from around the world are suitably well informed about these developments so that use of the resource increases substantially over the next few years.

Publications

10 25 50

publication icon
Alajmi K (2017) Development of breast cancer risk prediction for the UK population using the UK Biobank dataset in Cancer Epidemiology Biomarkers & Prevention

publication icon
Atkins JL (2019) Impact of Low Cardiovascular Risk Profiles on Geriatric Outcomes: Evidence From 421,000 Participants in Two Cohorts. in The journals of gerontology. Series A, Biological sciences and medical sciences

 
Description Biobank Enhancement 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution exome sequencing of 50,000 participants
Collaborator Contribution creating vast amounts of genetic data to be used by researchers accessing UKBiobank
Impact exome data
Start Year 2017
 
Description Biobank Enhancement 
Organisation Regeneron Pharmaceuticals, Inc.
Country United States 
Sector Private 
PI Contribution exome sequencing of 50,000 participants
Collaborator Contribution creating vast amounts of genetic data to be used by researchers accessing UKBiobank
Impact exome data
Start Year 2017
 
Description Genetic enhancement 
Organisation AbbVie Inc
Country Global 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Alnylam Pharmaceuticals
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Biogen Idec
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Bristol-Myers Squibb
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Pfizer Inc
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Regeneron Pharmaceuticals, Inc.
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Takeda Pharmaceutical Company
Department Takeda Pharmaceuticals U.S.A., Inc. (TPUSA)
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description UK Biobank Scientific Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London
Year(s) Of Engagement Activity 2018
 
Description UKBiobank participant events - 2014 - 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2019 over 3,000 participants have taken part in events in Edinburgh (2), Manchester (4), Nottingham, Leeds, Cardiff, Newcastle (4), Glasgow (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing)
Year(s) Of Engagement Activity 2014,2015,2016,2017,2018
URL http://www.ukbiobank.ac.uk